EUVIMEDEUVIMED entdecken
Systematische ÜbersichtVergleichsstudie

A cost-effectiveness analysis of the use of oral ibrexafungerp versus fluconazole for acute vulvovaginal candidiasis in the UK NHS primary care service

Viraj Shah, Anjali Cyril, Peter Koleoso, Arunesh Ragutharan, Mohammed Faiz, Pathusha Pushpakanthan

British Journal of General Practice · 2024

DOI: 10.3399/bjgp24x738189 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift British Journal of General Practice, 2024. Verfasst von Viraj Shah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Imperial College London. Hauptthemen laut MEDLINE: Fluconazole, Cost-Benefit Analysis, Candidiasis, Vulvovaginal, Antifungal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vulvovaginal Candidiasis (VVC) is a fungal infection causing inflammation of the vagina and/or the vulva. Symptoms include itching, irritation, and discharge. VVC presents commonly across primary care and, despite its mild symptoms, carries psychological burden and has a significant impact on women’s quality of life. UK guidelines support treatment via oral or topical azole antifungal agents. Recent evidence attests to the superiority of novel non-azole antifungals. Thus, rigorous financial assessment of both antifungals is necessary for optimal VVC treatment allocation in UK primary care.

Aim

To evaluate the cost-effectiveness of ibrexafungerp against the gold standard fluconazole as first-line treatment of VVC within the NHS.

Method

A systematic review on the efficacy of ibrexafungerp and fluconazole in acute VVC was conducted. Cost-effectiveness analysis was initiated using health outcome data from the DOVE trial, a Phase 2 RCT. Costs in pound sterling were ascertained in monetary units, and effectiveness determined as reduced need for follow-up medication.

Results

An incremental cost-effectiveness ratio of £2185.74 was determined. This suggests oral ibrexafungerp being largely more costly yet slightly more effective than fluconazole, and thus has unfavourable net benefit. Two sensitivity analyses were conducted considering follow-up medication combination and market price, which provided confidence in the calculated cost-effectiveness ratio.

Conclusion

This analysis highlights fluconazole’s cost-effectiveness in current UK guidelines and favourability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluconazoleCost-Benefit AnalysisCandidiasis, VulvovaginalAntifungal AgentsHumansFemaleAdministration, OralUnited KingdomAmphotericin BState MedicinePrimary Health CareAcute DiseaseTreatment OutcomeCost-Effectiveness AnalysisGlycosidesTriterpenes

Substanzen

FluconazoleAntifungal AgentsibrexafungerpAmphotericin BGlycosidesTriterpenes

Autor:innen und Institutionen

  • Imperial College London.

Zitieren

APA

Shah, V., Cyril, A., Koleoso, P., Ragutharan, A., Faiz, M., & Pushpakanthan, P. (2024). A cost-effectiveness analysis of the use of oral ibrexafungerp versus fluconazole for acute vulvovaginal candidiasis in the UK NHS primary care service. British Journal of General Practice. https://doi.org/10.3399/bjgp24x738189

Vancouver

Shah V, Cyril A, Koleoso P, Ragutharan A, Faiz M, Pushpakanthan P. A cost-effectiveness analysis of the use of oral ibrexafungerp versus fluconazole for acute vulvovaginal candidiasis in the UK NHS primary care service. British Journal of General Practice. 2024. doi:10.3399/bjgp24x738189

BibTeX
@article{Shah2024,
  author = {Shah, Viraj and Cyril, Anjali and Koleoso, Peter and Ragutharan, Arunesh and Faiz, Mohammed and Pushpakanthan, Pathusha},
  title = {A cost-effectiveness analysis of the use of oral ibrexafungerp versus fluconazole for acute vulvovaginal candidiasis in the UK NHS primary care service},
  journal = {British Journal of General Practice},
  year = {2024},
  doi = {10.3399/bjgp24x738189}
}
Kostenlos starten →